S1706: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

This study is being done to answer the following question: Can we lower the chance of your cancer returning by adding the drug Olaparib to the usual radiation therapy for your cancer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your inflammatory breast cancer. The usual approach is defined as care most people get for inflammatory breast cancer when they have already received chemotherapy and had surgery to remove the cancer.

Are you Eligible? (Inclusion Criteria)

• To be considered for this trial, subjects must have:
• inflammatory breast cancer without distant metastases confirmed by pathology
• completed neoadjuvant chemotherapy prior to mastectomy
• undergone modified radical mastectomy
• no history of radiation to the chest wall
• greater than or equal to 18 years of age
• ability to swallow and retain oral medications and have no known gastrointestinal disorders likely to interfere with absorption of the study medication